Filing Flows › Kymera Therapeutics (KYMR) › Q3 2025
Kymera Therapeutics (KYMR) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Kymera Therapeutics (KYMR) reported revenue of $2.8M for the third quarter 2025 (Q3 2025), -26% from a year earlier and -76% from the quarter before.
Kymera Therapeutics, Q3 2025: revenue $2.8M (-26% year over year), net loss $82.2M, operating cash flow −$27.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.8M | -76% | -26% |
| Operating profit | −$92.5M | — | — |
| Net earnings | −$82.2M | — | — |
| Operating cash flow | −$27.1M | — | — |
What changed
Revenue was $2.8M in Q3 2025, down 26% year over year and down 76% from the previous quarter.
Operating costs exceeded revenue by $92.5M, an operating margin of -3347.4%. Total costs grew 26% against a revenue fall of 26%. The quarter ended with a net loss of $82.2M, wider than the previous quarter's $76.6M loss.
Operating cash flow was −$27.1M. Non-cash charges added back $2.1M of depreciation and amortization and $15.8M of share-based compensation. Working capital and other items added $37.1M. Capital expenditures of $181K exceeded it, leaving free cash flow of −$27.3M.
Questions
What was Kymera Therapeutics' revenue in the third quarter 2025?
Kymera Therapeutics (KYMR) reported revenue of $2.8M for the third quarter 2025 (Q3 2025), -26% from a year earlier and -76% from the quarter before.